Trial reportDigestive diseases and sciences2026
Rifaximin Improves Frailty in Patients with Decompensated Cirrhosis: A Randomized Trial.
Trial report in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with decompensated cirrhosis have high prevalence of frailty that increases morbidity and mortality. This study was done to determine the impact of six months of Rifaximin therapy on frailty in patients with decompensated cirrhosis.
methods100 patients with frailty as assessed by Liver frailty Index (LFI > 4.5) at baseline were randomized 1:1 to receive standard medical therapy (SMT) plus Rifaximin (rSMT, intervention) versus SMT (control) alone. The primary outcome was an improvement in frailty at 6 months. Secondary outcome measures included improvement in CTP and MELD, inflammatory markers, hospitalization, and survival.
resultsFrailty improved significantly in the intervention arm as compared to the control arm (4.7(4.5-5.0) to 4.2(4.1-4.5), (P < 0.00) vs 4.7(4.6-5.0) to 4.7(4.4-5.2), (P = 0.70) at 6 months. The disease severity as assessed by CTP and MELD, scores showed a significant improvement in the rSMT group as compared to the SMT group (P < 0.05). The delta change in MELD score was -2.3 ± 2.9 versus 1.7 ± 5.4 (P < 0.00) in the intervention arm as compared to control arm. Inflammatory markers showed significant improvement, with a higher delta change in IL-6 in the intervention arm (-10 [-15.7/-4.4] vs -5 [-10.2/-0.5]; P = 0.01). The patients in rSMT arm had lesser number of hospitalizations 8(16%) vs 26(52%); P < 0.00) over the course of 6 months. The mortality in rSMT and SMT arms was 10% (n = 5), and 22% (n = 11), respectively though there was no significant difference in the overall survival (P = 0.11).
conclusionRifaximin therapy in decompensated cirrhosis has a significant impact on improving frailty and disease severity, with a reduction in hospitalization rate. CLINICAL TRIAL REGISTRY NUMBER: CTRI/2023/01/048824.
Indexed as
Identifiers
41579272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.